検索結果 - Javier Pinilla‐Ibarz
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells 著者: Rena J. May, Tao Dao, Javier Pinilla‐Ibarz, Tatyana Korontsvit, Victoriya Zakhaleva, Rong H. Zhang, P. Maslak, David A. Scheinberg
出版事項 2007Artigo -
10
Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance 著者: Hagop M. Kantarjian, Phillipp le Coutre, Jorge E. Cortés, Javier Pinilla‐Ibarz, Arnon Nagler, Andreas Hochhaus, Shinya Kimura, Oliver G. Ottmann
出版事項 2010Artigo -
11
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease 著者: Kendra Sweet, Lori Hazlehurst, Eva Sahakian, John J. Powers, Lisa Nodzon, Fadi Kayali, Kelly A. Hyland, Ashley Nelson, Javier Pinilla‐Ibarz
出版事項 2018Artigo -
12
Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of... 著者: Constantine S. Tam, Javier Pinilla Ibarz, Volkan Karakuş, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Nicolás Piotrowsky, Martin Šimkovič, Andrew Smith, Stephan Stilgenbauer
出版事項 2022Artigo -
13
-
14
NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia 著者: Susan O’Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla‐Ibarz, Jerald P. Radich, Paul J. Shami, Benjamin D. Smith, David S. Snyder, Hema Sundar, Moshe Talpaz, Meir Wetzler
出版事項 2011Artigo -
15
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance 著者: Alejandro Villagra, Fengdong Cheng, Hongwei Wang, Ildelfonso Suarez, Michelle Glozak, Michelle Maurin, Danny Nguyen, Kenneth L. Wright, Peter Atadja, Kapil N. Bhalla, Javier Pinilla‐Ibarz, Edward Seto, Eduardo M. Sotomayor
出版事項 2008Artigo -
16
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison 著者: Kristin M. Phillips, Javier Pinilla‐Ibarz, Eduardo M. Sotomayor, Morgan Lee, Heather Jim, Brent J. Small, Lubomir Sokol, Jeffrey E. Lancet, Sara Tinsley, Kendra Sweet, Rami S. Komrokji, Paul B. Jacobsen
出版事項 2012Artigo -
17
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes 著者: Asmita Mishra, Maria Corrales‐Yepez, Najla Al Ali, Mohamed A. Kharfan‐Dabaja, Eric Padron, Ling Zhang, Pearlie K. Epling‐Burnette, Javier Pinilla‐Ibarz, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji
出版事項 2013Artigo -
18
PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY 著者: Constantine S. Tam, Javier Pinilla‐Ibarz, Volkan Karakuş, Miguel Arturo Pavlovsky, Stephan Stilgebauer, Martin Šimkovič, Ana Cristina Fenili, Miguel Augusto Miroli, Carolina García-Castillo, Kathryn Huntley, Catherine Moura, Fernando Piotrowski, Mervat Mattar
出版事項 2023Artigo -
19
Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL 著者: Constantine S. Tam, Javier Pinilla‐Ibarz, Carolina García-Castillo, Ana Cristina Fenili, Kathryn Huntley, Volkan Karakuş, Mervat Mattar, Miguel Augusto Miroli, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Piotrowski, Martin Šimkovič, Stephan Stilgenbauer
出版事項 2023Artigo -
20
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib 著者: Jorge E. Cortés, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla‐Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, Michele Baccarani
出版事項 2011Artigo
関連主題
Medicine
Internal medicine
Immunology
Biology
Cancer research
Oncology
Genetics
Myeloid leukemia
Leukemia
Imatinib
Gene
Chronic lymphocytic leukemia
Cell biology
Dasatinib
Cancer
Histone
Histone deacetylase
Immune system
Bone marrow
Gastroenterology
Nilotinib
Adverse effect
Biochemistry
Immunotherapy
Lymphoma
Ponatinib
Confidence interval
HDAC6
Hazard ratio
Receptor